Conclusions
- There is considerable debate as to how SGLT2 inhibitors improve CV outcomes.
- SGLT2 inhibitors have clear diuretic effects and improve volume status without many of the traditional adverse effects of diuretics.
- Even if SGLT2 inhibitors may be added late to the medication regimen in patients with HF, clinical adoption is likely to be extensive and facilitated by the excellent safety profile of these drugs.
- Decreasing incident T2D could be considered as an additional benefit of dapagliflozin.